Search Results

You are looking at 241 - 250 of 491 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

A Change of Heart

Crystal S. Denlinger

guidelines, visit 4. Romond EH Jeong JH Rastogi P . Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab

Full access

New Treatment Guidelines for Penile Cancer

Philippe E. Spiess

distant disease) were treated with neoadjuvant chemotherapy (paclitaxel, ifosfamide, and cisplatin) and then surgical resection. They reported an objective response rate of 50%. “On the whole, this is far superior to what we see traditionally with surgery

Full access

Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013

Talia Golan, Tal Sella, Ofer Margalit, Uri Amit, Naama Halpern, Dan Aderka, Einat Shacham-Shmueli, Damien Urban, and Yaacov Richard Lawrence

a significant benefit in OS over gemcitabine monotherapy, until recently. In 2011 and 2013, progress was made with the publication of the PRODIGE 4/ACCORD 11 4 and MPACT 5 studies, showing survival benefits for FOLFIRINOX and gemcitabine/nab-paclitaxel

Full access

Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report

Quanying Tang, Tong Li, Fan Ren, Xuanguang Li, WeiBo Cao, Haochuan Yu, Fuling Mao, Cancan Cao, Lingling Zu, and Song Xu

have suggested that KANK1 , a tumor suppressor gene, can mediate paclitaxel resistance in lung adenocarcinoma A549 cells. In addition, a previous study also reported a pancreatic neuroendocrine carcinoma patient with a KANK1::ALK fusion who exhibited

Full access

Updates in the Treatment of Metastatic Urothelial Cancer

Presented by: Thomas W. Flaig

, paclitaxel, or vinflunine). 2 Key findings from the study included an improved overall response rate (ORR) with enfortumab vedotin (40.6%) compared with standard chemotherapy (17.9%). Complete response rates were also increased with enfortumab vedotin (4

Full access

Advances in the Management of Metastatic Breast Cancer

Presented by: William J. Gradishar

chemotherapy as a first-line treatment of PD-L1–positive TNBC. The study compared pertuzumab and chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) with chemotherapy alone in patients who had not received prior treatment of metastatic disease

Full access

Updates in the Management of Hepatobiliary Cancers

Presented by: Mitesh J. Borad

doublet regimen with a significant improvement in OS, paved the way for SWOG 1815, which compared gemcitabine, cisplatin, and nab-paclitaxel with gemcitabine + cisplatin. Although there was a numerical improvement in PFS, OS, and response rates among the

Full access

Esophageal and Esophagogastric Junction Cancers

Jaffer A. Ajani, James S. Barthel, David J. Bentrem, Thomas A. D'Amico, Prajnan Das, Crystal S. Denlinger, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, Raymond U. Osarogiagbon, James A. Posey, Aaron R. Sasson, Walter J. Scott, Stephen Shibata, Vivian E. M. Strong, Thomas K. Varghese Jr., Graham Warren, Mary Kay Washington, Christopher Willett, and Cameron D. Wright

chemoradiation with carboplatin and paclitaxel was also well-tolerated, resulting in superior overall and disease-specific survivals compared with cisplatin and irinotecan in patients with locally advanced esophageal cancer. 136 In a retrospective study

Full access

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, and Gary H. Lyman

standard regimen. As shown in Figure 2 , RDI less than 85% ranged from 15.6% for patients with breast cancer treated with dose-dense AC followed by paclitaxel every 2 weeks to 87.6% for patients with CRC treated with 5-FU (every 8 weeks). Colony

Full access

Off-Label Use of Oncology Drugs: Too Much, Too Little, or Just Right?

Harold J. Burstein

constitute what most observers would consider appropriate use. The 10 drugs in this analysis (albumin-bound paclitaxel, azacytidine, bevacizumab, bortezomib, cetuximab, docetaxel, gemcitabine, pemetrexed, rituximab, and trastuzumab) are products well